Navigation Links
Merrimack Debuts New Website
Date:9/24/2015

CAMBRIDGE, Mass., Sept. 24, 2015 /PRNewswire/ -- Merrimack (NASDAQ: MACK), a biopharmaceutical company that applies systems biology to develop cancer treatments and diagnostics, today announced the debut of its new website, www.merrimack.com. The company also announced it has adopted Merrimack as its brand name and "Cures are built" as its tagline.  

"We are pleased to announce the debut of our new website, which was designed to enhance the user experience, with easier navigation and a clearer presentation of Merrimack's broader capabilities. We aren't just developing new therapies to treat cancer, we're also identifying novel biomarkers and creating companion diagnostics to help ensure that cancer patients don't receive treatments unlikely to benefit them," said Bob Mulroy, Merrimack CEO. "With this new website we hope to convey our dedication to applying systems engineering to better understand the complex, multi-dimensional aspects of cancer."

As part of the new website, Merrimack presents cancer as "the ultimate engineering challenge" and provides information about the company's pipeline, clinical trials and integrated approach to bringing precision diagnostics together with new treatment regimens.

About Merrimack

Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. With five candidates in clinical trials, several in preclinical development and multiple biomarkers designed to support patient selection, Merrimack is building one of the most robust oncology pipelines in the industry. Merrimack has a New Drug Application under review for its lead product candidate, MM-398, for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. For more information, please visit Merrimack's website at www.merrimack.com or connect on Twitter at @MerrimackPharma.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

CONTACT:
Dana Robie
Merrimack
617-441-7408
drobie@merrimack.com

Logo- http://photos.prnewswire.com/prnh/20150325/194550LOGO

 


'/>"/>
SOURCE Merrimack
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. Merrimack Pharmaceuticals Announces Expansion of MM-398 (nal-IRI) Imaging Study to Patients with Metastatic Breast Cancer
2. Merrimack Pharmaceuticals Reports First Quarter 2015 Financial Results
3. Technical Coverage of Biotech Stocks - Dyax, Alexion Pharma, Peregrine Pharma, Merrimack Pharma, and BioMarin Pharma
4. Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL
5. Brady Debuts New GHS FAQ Page on BradyID.com
6. Infocast’s Sustainable Chemicals & Plastic Adoptions & Applications Summit Debuts This September in San Diego
7. Brady Debuts “Evolve Your Lab in 4 Steps” Guidebook
8. ReliantHeart Debuts the VAD Maintenance System at ISHLT, April 15 -17th in Nice, France
9. Innovation & Tech Today Debuts STEM Section; Within Spring Issue on Newsstands April 9 In Partnership With The USA Science & Engineering Festival
10. Brady Debuts New Lab Label Testimonial Video
11. AACC Debuts Refreshed Brand Identity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2018)... ... 31, 2018 , ... Leading regenerative veterinary medicine company, VetStem ... using adipose tissue-derived stem cells to treat or prevent inflammation at the site ... Canada specifically, VetStem has been issued similar patents that cover the United States ...
(Date:7/25/2018)... ... 2018 , ... Eileen Meagher, an evidence-based energy healer, announces ... nutraceutical to improve skin health parameters including anti-wrinkling, skin hydration, elasticity and firmness. ... following results:,     More than 500% increase in cell growth ...
(Date:7/25/2018)... ... July 25, 2018 , ... John McDonald, CEO of ... of the Indiana India Business Council (IIBC), an advocacy group to strengthen economic ... board of directors, McDonald joins an impressive roster of local and national business ...
(Date:7/22/2018)... SOUTH JORDAN, Utah and BOSTON, Mass. (PRWEB) , ... ... ... proud to announce that Adam Pottorff, a driven channel professional has joined their ... record of excellence in leading business-growth initiatives, Adam will deliver his expertise as ...
Breaking Biology Technology:
(Date:8/14/2018)... ... 2018 , ... ActiGraph , the leading provider of ... today the establishment of a new Scientific Affairs and Data Management division. ... collaborations with ActiGraph’s academic and pharmaceutical industry partners to advance the development of ...
(Date:8/14/2018)... ... August 14, 2018 , ... From reconstruction of ... to a better understanding of congenital heart defects, 3-D printing is providing exciting ... special issue of Birth Defects Research (DOI: 10.1002/bdr2.1367). , ...
(Date:8/9/2018)... ... August 08, 2018 , ... Plum Alley Investments, an ... and healthcare companies, has invested in a sought-after $23 million Series A round ... Technology and Mammoth Biosciences , The biotech company is bringing to market the ...
Breaking Biology News(10 mins):